Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Decreases By 5.8%

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the target of a large decline in short interest in December. As of December 31st, there was short interest totalling 7,470,000 shares, a decline of 5.8% from the December 15th total of 7,930,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is presently 5.5 days. Approximately 8.6% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. American Century Companies Inc. acquired a new stake in shares of GoodRx in the second quarter valued at approximately $18,183,000. XTX Topco Ltd lifted its holdings in GoodRx by 42.4% during the 2nd quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock valued at $231,000 after purchasing an additional 8,801 shares during the last quarter. Canada Pension Plan Investment Board boosted its position in GoodRx by 5.9% during the second quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock worth $1,296,000 after purchasing an additional 9,200 shares during the period. Rubric Capital Management LP boosted its holdings in shares of GoodRx by 76.5% during the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock worth $29,147,000 after buying an additional 1,619,748 shares during the period. Finally, Marshall Wace LLP acquired a new position in GoodRx in the 2nd quarter valued at about $843,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Up 3.4 %

Shares of NASDAQ:GDRX traded up $0.15 during midday trading on Friday, reaching $4.57. The company had a trading volume of 1,843,665 shares, compared to its average volume of 1,056,958. The business’s 50 day moving average price is $4.59 and its 200 day moving average price is $6.44. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a market cap of $1.74 billion, a PE ratio of -152.33, a P/E/G ratio of 2.30 and a beta of 1.27.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GDRX. Barclays decreased their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Morgan Stanley dropped their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. KeyCorp reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Mizuho assumed coverage on shares of GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective on the stock. Finally, Citigroup dropped their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research report on Friday, January 10th. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.38.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.